We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
+$28.4M
Cap. Flow
-$577M
Cap. Flow %
-26.84%
Top 10 Hldgs %
29.86%
Holding
143
New
30
Increased
17
Reduced
35
Closed
30

Top Buys

Rank Stock Value
1
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$75.8M
2
THOR
THORATEC CORPORATION
THOR
+$31.1M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$30.7M
4
VTRS icon
Viatris
VTRS
+$27.4M
5
TRAW icon
Traws Pharma
TRAW
+$24.3M

Top Sells

Rank Stock Value
1
OPTR
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
+$43.8M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$42.7M
3
NKTR icon
Nektar Therapeutics
NKTR
+$34M
4
STJ
St Jude Medical
STJ
+$24M
5
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 52.2%
2 Technology 1.35%
3 Financials 1.05%
4 Consumer Discretionary 0%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GEVA
76
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$3.17M 0.15%
+50,000
New +$2.46M
LCAV
77
DELISTED
LCA-VISION INC
LCAV
$2.63M 0.12%
730,856
-100,000
-12% -$355K
SQNM
78
DELISTED
SEQUENOM INC NEW
SQNM
$2.63M 0.12%
+985,000
New +$3.31M
DRTX
79
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$2.5M 0.12%
275,979
-476,560
-63% -$3.95M
WINT
80
DELISTED
Windtree Therapeutics Inc
WINT
$2.33M 0.11%
84,857
-10,357
-11% -$251K
DNDN
81
PUT
DELISTED
DENDREON CORPORATION
DNDN
$2.05M 0.1%
700,000
-1,800,000
-72% -$6.66M
HOLX
82
DELISTED
Hologic
HOLX
$1.99M 0.09%
96,330
+61,330
+175% +$1.31M
ELN
83
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
$1.56M 0.07%
100,000
-65,084
-39% -$981K
PTN
84
Palatin Technologies
PTN
$16.2M
$1.38M 0.06%
1,600
– –
IRWD icon
85
PUT
Ironwood Pharmaceuticals
IRWD
$635M
$1.18M 0.06%
119,400
– –
SVRA icon
86
Savara
SVRA
$1.13B
$1.16M 0.05%
37,632
-18,772
-33% -$583K
ONCT
87
CALL
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.01M 0.05%
+357
New +$1.78M
BAX icon
88
Baxter International
BAX
$11.7B
$985K 0.05%
+27,615
New +$1.07M
SLTM
89
DELISTED
SOLTA MED INC (DE)
SLTM
$702K 0.03%
339,063
– –
ECYT
90
DELISTED
Endocyte, Inc. Common Stock
ECYT
$672K 0.03%
50,430
+22,722
+82% +$359K
AVNR
91
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$656K 0.03%
+155,000
New +$734K
SPHS
92
DELISTED
Sophiris Bio, Inc.
SPHS
$578K 0.03%
+123,585
New +$570K
CTRX
93
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$574K 0.03%
12,500
-17,500
-58% -$924K
XTNT icon
94
Xtant Medical Holdings
XTNT
$63.1M
$517K 0.02%
6,431
-9,606
-60% -$690K
BRKR icon
95
Bruker
BRKR
$8.86B
$434K 0.02%
+21,000
New +$401K
ICAD
96
DELISTED
iCAD Inc
ICAD
$205K 0.01%
38,887
– –
OREX
97
DELISTED
Orexigen Therapeutics, Inc.
OREX
$138K 0.01%
2,258
– –
ACAD icon
98
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-1,067,115
Closed -$19.4M
ALKS icon
99
Alkermes
ALKS
$8.79B
– –
-11,000
Closed -$315K
AMED
100
DELISTED
Amedisys
AMED
– –
-233,066
Closed -$2.7M
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2013 Portfolio in Review

As of Q3 2013, Deerfield Management held 143 positions worth $2.15B, up 1.3% from $2.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Deerfield Management withdrew a net $577M in Q3 2013, closing 30 positions and reducing 35 holdings. Its most notable exit was OPTIMER PHARMACEUTICALS, INC. COM STK, an estimated $43.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 51% a quarter earlier, followed by Technology and Financials.

Against the trend, Deerfield Management opened a new position in PROSENSA HLDGS N V ORD SHS (NLD) worth $21.3M.

  • Deerfield Management's largest Q3 2013 buy was PROSENSA HLDGS N V ORD SHS (NLD): 3,224,524 shares worth $21.3M.
  • Deerfield Management added most to Spectrum Pharmaceuticals Inc in Q3 2013, an estimated $24.3M increase.
  • Deerfield Management's biggest Q3 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $42.7M.
  • Deerfield Management fully exited OPTIMER PHARMACEUTICALS, INC. COM STK in Q3 2013, selling an estimated $43.8M.
  • Deerfield Management's ten largest holdings make up 30% of its $2.15B portfolio in Q3 2013.
  • Deerfield Management opened 30 new positions and closed 30 in Q3 2013.
  • Deerfield Management's portfolio value rose 1.3% quarter-over-quarter to $2.15B.

Based on Deerfield Management's 13F filing for Q3 2013, filed 14 Nov 2013.